Upcoming biological therapies in systemic lupus erythematosus

International Immunopharmacology

Volumn 27, Issue 2, 2015, Pages 189-193

  Sciascia, Savino ^a,b   Talavera Garcia, Eva ^c   Roccatello, Dario ^a   Baldovino, Simone ^a   Mengatti, Elisa ^a   Cuadrado, Maria Jose ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Belimumab; Biological agents; Rituximab; Systemic lupus erythematosus

Indexed keywords

ABETIMUS; BELIMUMAB; BIOLOGICAL PRODUCT; BLISIBIMOD; BORTEZOMIB; EDRATIDE; EPRATUZUMAB; FORIGERIMOD; LAQUINIMOD; OCRELIZUMAB; PROTEASOME; RITUXIMAB; RONTALIZUMAB; SIFALIMUMAB; SIRUKUMAB; TABALUMAB; TOCILIZUMAB;

ARTICLE; B CELL TARGETED THERAPY; B LYMPHOCYTE; BIOLOGICAL THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL TARGETED THERAPY; T LYMPHOCYTE; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; LUPUS ERYTHEMATOSUS, SYSTEMIC;

ANIMALS; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84937253235     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2015.04.049     Document Type: Review

References (51)

1. V.S. Chan, H.H. Tsang, R.C. Tam, L. Lu, and C.S. Lau B-cell-targeted therapies in systemic lupus erythematosus Cell. Mol. Immunol. 10 2013 133 142
2. S.V. Navarra, R.M. Guzman, A.E. Gallacher, S. Hall, R.A. Levy, R.E. Jimenez, E.K. Li, M. Thomas, H.Y. Kim, M.G. Leon, C. Tanasescu, E. Nasonov, J.L. Lan, L. Pineda, Z.J. Zhong, W. Freimuth, and M.A. Petri Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo controlled, phase 3 trial Lancet 377 2011 721 731
3. M. Ramos-Casals, I. Sanz, X. Bosch, J.H. Stone, and M.A. Khamashta B-cell depleting therapy in systemic lupus erythematosus Am. J. Med. 125 2012 327 336
4. N. Jordan, and D.P. D'Cruz Belimumab for the treatment of systemic lupus erythematosus Expert. Rev. Clin. Immunol. 11 2015 195 204
5. M. Ramos-Casals, M.J. Soto, M.J. Cuadrado, and M.A. Khamashta Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases Lupus 18 2009 767 776
6. J.T. Merrill, C.M. Neuwelt, D.J. Wallace, J.C. Shanahan, K.M. Latinis, J.C. Oates, T.O. Utset, C. Gordon, D.A. Isenberg, H.J. Hsieh, D. Zhang, and P.G. Brunetta Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum. 62 2010 222 233
7. B.H. Rovin, R. Furie, K. Latinis, R.J. Looney, F.C. Fervenza, J. SanchezGuerrero, R. Maciuca, D. Zhang, J.P. Garg, P. Brunetta, and G. Appel Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study Arthritis Rheum. 64 2012 1215 1226
8. T.Y. Lu, T. Jonsdottir, R.F. van Vollenhoven, and D.A. Isenberg Prolonged B cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases Ann. Rheum. Dis. 67 2008 1493 1494
9. T.L. Rivera, H.M. Belmont, S. Malani, M. Latorre, L. Benton, J. Weisstuch, L. Barisoni, C.E. Tseng, P.M. Izmirly, J.P. Buyon, and A.D. Askanase Current therapies for lupus nephritis in an ethnically heterogeneous cohort J. Rheumatol. 36 2009 298 305
10. V. Reddy, D. Jayne, D. Close, and D. Isenberg B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design Arthritis Res. Ther. 15 Suppl. 1 2013 S2
11. E.F. Mysler, A.J. Spindler, R. Guzman, M. Bijl, D. Jayne, R.A. Furie, F.A. Houssiau, J. Drappa, D. Close, R. Maciuca, K. Rao, S. Shahdad, and P. Brunetta Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study Arthritis Rheum. 65 2013 2368 2379
12. D.J. Wallace, and D.M. Goldenberg Epratuzumab for systemic lupus erythematosus Lupus 22 2013 400 405
13. D.J. Wallace, C. Gordon, V. Strand, K. Hobbs, M. Petri, K. Kalunian, F. Houssiau, P.P. Tak, D.A. Isenberg, L. Kelley, B. Kilgallen, A.N. Barry, W.A. Wegener, and D.M. Goldenberg Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up Rheumatology (Oxford) 52 2013 1313 1322
14. UCB Announces Start of Phase III Programme with Epratuzumab for Patients with Moderate to Severe Systemic Lupus Erythematosus [Press release]. [Accessed on 19/09/2014]. Available from: http://wwwucbpresscentrecom/News/UCB-announces-start-of-phase-IIIprogramme-with-epratuzumab-for-patients-with-moderate-to-severe-sys-1a4aspx 2010
15. D.J. Wallace, K. Kalunian, M.A. Petri, V. Strand, F.A. Houssiau, M. Pike, B. Kilgallen, S. Bongardt, A. Barry, L. Kelley, and C. Gordon Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study Ann. Rheum. Dis. 73 2014 183 190
16. M.P. Cancro, D.P. D'Cruz, and M.A. Khamashta The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus J. Clin. Invest. 119 2009 1066 1073
17. R. Furie, M. Petri, O. Zamani, R. Cervera, D.J. Wallace, D. Tegzova, J. Sanchez-Guerrero, A. Schwarting, J.T. Merrill, W.W. Chatham, W. Stohl, E.M. Ginzler, D.R. Hough, Z.J. Zhong, W. Freimuth, and R.F. van Vollenhoven A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus Arthritis Rheum. 63 2011 3918 3930
18. J.T. Merrill, E.M. Ginzler, D.J. Wallace, J.D. McKay, J.R. Lisse, C. Aranow, F.R. Wellborne, M. Burnette, J. Condemi, Z.J. Zhong, L. Pineda, J. Klein, and W.W. Freimuth Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus Arthritis Rheum. 64 2012 3364 3373
19. B.H. Hahn Belimumab for systemic lupus erythematosus N. Engl. J. Med. 368 2013 1528 1535
20. E.M. Ginzler, D.J. Wallace, J.T. Merrill, R.A. Furie, W. Stohl, W.W. Chatham, A. Weinstein, J.D. McKay, W.J. McCune, Z.J. Zhong, W.W. Freimuth, and M.A. Petri Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus J. Rheumatol. 41 2014 300 309
21. M.A. Dooley, F. Houssiau, C. Aranow, D.P. D'Cruz, A. Askanase, D.A. Roth, Z.J. Zhong, S. Cooper, W.W. Freimuth, and E.M. Ginzler Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE Lupus 22 2013 63 72
22. ClinicalTrials.gov [Internet] Identifier NCT01395745. A Randomised, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects with Systemic Lupus Erythematosus (CHABLIS-SC1); 14th July 2011 - [Cited 8th April 2014]; [About 6 Screens] Feb 29th 2000 National Library of Medicine (US) Bethesda (MD) (Available from: http://clinicaltrials.gov/ct2/show/NCT01395745)
23. ClinicalTrials.gov [Internet] Identifier NCT01196091. A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) Feb 29th 2000 National Library of Medicine (US) Bethesda (MD) (Available from: http://clinicaltrials.gov/ct2/show/NCT01196091)
24. W. Stohl Biologic differences between various inhibitors of the BLyS/BAFF pathway: should we expect differences between belimumab and other inhibitors in development? Curr. Rheumatol. Rep. 14 2012 303 309 (Available at: https://investor.lilly.com/releasedetail.cfm)
25. J. Zhang, V. Roschke, K.P. Baker, Z. Wang, G.S. Alarcon, B.J. Fessler, H. Bastian, R.P. Kimberly, and T. Zhou Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus J. Immunol. 166 2001 6 10
26. M. Dall'Era, E. Chakravarty, D. Wallace, M. Genovese, M. Weisman, A. Kavanaugh, K. Kalunian, P. Dhar, E. Vincent, C. Pena-Rossi, and D. Wofsy Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial Arthritis Rheum. 56 2007 4142 4150
27. E.M. Ginzler, S. Wax, A. Rajeswaran, S. Copt, J. Hillson, E. Ramos, and N.G. Singer Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial Arthritis Res. Ther. 14 2012 R33
28. A. Sharabi, H. Azulai, Z.M. Sthoeger, and E. Mozes Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action Immunology 121 2007 248 257
29. Z.M. Sthoeger, A. Sharabi, M. Dayan, H. Zinger, I. Asher, U. Sela, and E. Mozes The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients Hum. Immunol. 70 2009 139 145
30. Z. Sthoeger, H. Zinger, A. Sharabi, I. Asher, and E. Mozes The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-alpha in murine and human systemic lupus erythematosus PLoS ONE 8 2013 10
31. M.I.D. Urowitz, D.J. Wallace, and PRELUDE Study Group Prelude-edratide phase II study outcome - from predefined analyses to more recent assessment approaches [abstract] Ann. Rheum. Dis. 2011 315
32. F. Monneaux, J.M. Lozano, M.E. Patarroyo, J.P. Briand, and S. Muller T cell recognition and therapeutic effect of a phosphorylated synthetic peptide of the 70K snRNP protein administered in MR/lpr mice Eur. J. Immunol. 33 2003 287 296
33. F. Monneaux, V. Parietti, J.P. Briand, and S. Muller Importance of spliceosomal RNP1 motif for intermolecular T-B cell spreading and tolerance restoration in lupus Arthritis Res. Ther. 9 2007 10
34. S. Muller, F. Monneaux, N. Schall, R.K. Rashkov, B.A. Oparanov, P. Wiesel, J.M. Geiger, and R. Zimmer Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial Arthritis Rheum. 58 2008 3873 3883
35. R. Zimmer, H.R. Scherbarth, O.L. Rillo, J.J. Gomez-Reino, and S. Muller Lupuzor/P140 peptide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled phase IIb clinical trial Ann. Rheum. Dis. 72 2013 1830 1835
36. W. Bruck, and S.S. Zamvil Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis Expert. Rev. Clin. Pharmacol. 5 2012 245 256
37. D.A.G. Jayne, T.M. Chan, and et al. A Randomized Controlled Study of Laquinimod in Active Lupus Nephritis Patients in Combination with Standard of Care 2013 164
38. M. Mosca, C. Baldini, and S. Bombardieri LJP-394 (abetimus sodium) in the treatment of systemic lupus erythematosus Expert Opin. Pharmacother. 8 2007 873 879
39. V. Strand, C. Aranow, M.H. Cardiel, D. Alarcon-Segovia, R. Furie, Y. Sherrer, J. Tumlin, D.J. Wallace, and B. Crawford Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo Lupus 12 2003 677 686
40. R.A. Furie, J.M. Cash, M.E. Cronin, R.S. Katz, M.H. Weisman, C. Aranow, M.R. Liebling, N.P. Hudson, C.M. Berner, S. Coutts, and H.A. de Haan Treatment of systemic lupus erythematosus with LJP 394 J. Rheumatol. 28 2001 257 265
41. D. Alarcon-Segovia, J.A. Tumlin, R.A. Furie, J.D. McKay, M.H. Cardiel, V. Strand, R.G. Bagin, M.D. Linnik, and B. Hepburn LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study Arthritis Rheum. 48 2003 442 454
42. M.H. Cardiel, J.A. Tumlin, R.A. Furie, D.J. Wallace, T. Joh, and M.D. Linnik Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial Arthritis Rheum. 58 2008 2470 2480
43. D.M. Horowitz, and R.A. Furie Abetimus sodium: a medication for the prevention of lupus nephritis flares Expert. Opin. Pharmacother. 10 2009 1501 1507
44. K. Frohlich, J.U. Holle, P.M. Aries, W.L. Gross, and F. Moosig Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma Ann. Rheum. Dis. 70 2011 1344 1345
45. G.G. Illei, Y. Shirota, C.H. Yarboro, J. Daruwalla, E. Tackey, K. Takada, T. Fleisher, J.E. Balow, and P.E. Lipsky Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study Arthritis Rheum. 62 2010 542 552
46. J.C. Szepietowski, S. Nilganuwong, A. Wozniacka, A. Kuhn, F. Nyberg, R.F. van Vollenhoven, A.A. Bengtsson, A. Reich, D.E. de Vries, B. van Hartingsveldt, D.W. Robinson Jr., R. Gordon, and B. Hsu Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus Arthritis Rheum. 65 2013 2661 2671 10.1002/art.38091
47. Z. Sthoeger, A. Sharabi, and E. Mozes Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus J. Autoimmun. 54 2014 60 71
48. M. Petri, D.J. Wallace, A. Spindler, V. Chindalore, K. Kalunian, E. Mysler, C.M. Neuwelt, G. Robbie, W.I. White, B.W. Higgs, Y. Yao, L. Wang, D. Ethgen, and W. Greth Sifalimumab, a human anti-interferon-alpha monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, doseescalation study Arthritis Rheum. 65 2013 1011 1021
49. AstraZeneca AstraZeneca Announces MedImmune's Mavrilimumab and Sifalimumab Both Met Primary Endpoints in Phase IIb Studies http://wwwastrazenecacom/Media/Pressreleases/Article/20140512-astrazeneca-announces-medimmunesmavrilimumab-sifalimumab-met-primary-endpoints-Phase-IIb-studies 2014
50. J.M. McBride, J. Jiang, A.R. Abbas, A. Morimoto, J. Li, R. Maciuca, M. Townsend, D.J. Wallace, W.P. Kennedy, and J. Drappa Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, doseescalation study Arthritis Rheum. 64 2012 3666 3676
51. B.R. Lauwerys, E. Hachulla, F. Spertini, E. Lazaro, C. Jorgensen, X. Mariette, E. Haelterman, G. Grouard-Vogel, B. Fanget, O. Dhellin, P. Vandepapeliere, and F.A. Houssiau Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid Arthritis Rheum. 65 2013 447 456